Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atenativ in Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
NCT04918173Phase 3Recruiting
- Sponsor
- Octapharma
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of antithrombin III concentrate in congenital antithrombin deficiency (ATD), sponsored by Octapharma. Primary endpoint: Incidence of thrombotic events at 30 days. Started Jul 2022; status: recruiting.
02
Drugs
antithrombin III concentrate
03
Conditions
congenital antithrombin deficiency (ATD)
Beyond the preview
Go deeper on NCT04918173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04918173.